Following Up Is Hard to Do: Postoperative Pneumothorax in the Era of Mobility and Privacy

Donald Trump’s push to dismantle diversity, equity, and inclusion (D.E.I.) programs isn’t just affecting marginalized groups—it’s also hitting rural, white Americans harder than expected. Many of these communities rely on federal grants and initiatives tied to D.E.I. for things like job training, healthcare access, and small-business support. Without those resources, they’re feeling the pinch, too.

RFK Jr. has abruptly canceled a meeting of a crucial preventive health panel that decides which screenings and preventive care services insurers must cover. This comes just weeks after he fired 17 members of a CDC vaccine advisory committee, claiming it would rebuild trust in vaccines—a move that’s sparked debate about his approach to public health oversight.

Editor’s Note: These actions signal a shake-up in how key health decisions are made—and who gets to make them. The preventive task force affects millions of Americans’ access to early detection and care, while the CDC committee firings raise questions about politicization of vaccine guidance. Whether this actually boosts trust—or just fuels more uncertainty—remains to be seen.

NASA and SpaceX are gearing up to launch the Crew-11 mission on July 31, sending a team of four astronauts—some newbies, some seasoned pros—to the International Space Station. It’s another milestone in their ongoing partnership to keep the ISS crewed and science humming along in orbit.

Editor’s Note: This isn’t just another rocket launch—it’s a sign of how routine crewed spaceflight is becoming, thanks to NASA and SpaceX’s collaboration. With a mix of fresh faces and experienced astronauts, the mission keeps the ISS fully staffed for critical research while giving newer spacefarers a chance to cut their teeth. For space nerds, it’s a reminder that the era of commercial space travel is here to stay.

Remember those weird Soviet hoverboats from the Cold War that looked like something out of a sci-fi flick? Turns out they weren’t just a failed experiment after all. Both China and the U.S. are dusting off the old blueprints and reviving these sea-skimming crafts—part boat, part aircraft—as tensions rise in the Pacific. It’s a case of old tech getting a new lease on life, but this time with higher stakes.

Editor’s Note: The world’s superpowers are digging into history’s toolbox to prepare for potential future conflicts, and that includes bringing back oddball tech like hoverboats. It’s a sign that the Pacific could become a flashpoint, and both sides are scrambling for any edge—even if it means resurrecting ideas once left for dead. For military watchers, it’s a fascinating twist; for everyone else, it’s a reminder that old Cold War ghosts might not stay buried.

The FDA has released a batch of letters highlighting their initial concerns about certain new drugs—most of which were already publicly available. While these drugs eventually got the green light, the letters show the regulatory hurdles they faced early on, with FDA Commissioner Dr. Marty Makary involved in the process.

Editor’s Note: This isn’t a scandal—it’s more like a behind-the-scenes look at how the FDA scrutinizes new meds before approval. The fact that these drugs eventually passed suggests the system works, but it’s still interesting to see where regulators drew the line. For patients and investors, it’s a reminder that even successful drugs face tough questions first.